Oncopharmpod
Tepotinib
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:15:30
- Mas informaciones
Informações:
Sinopsis
In light of teptinib's recent FDA-approval for exon-14 skipping MET altered metastatic NSLCC, we compare tepotinib to its predecessor in this space - capmatinib.
